A 43-year-old woman with breast cancer receiving doxorubicin presents with progressive dyspnea and fatigue. Vital signs show BP 128/82 mmHg, HR 102 bpm, RR 18/min, and SpO2 98% on room air. Echocardiography reveals a declining left ventricular ejection fraction of 35% (previously 55%). Troponin is mildly elevated at 0.08 ng/mL. She denies chest pain. Which agent can reduce the risk of this doxorubicin-induced cardiotoxicity?
- A)Leucovorin
- B)Protamine sulfate
- C)Succimer
- D)Mesna
- E)DexrazoxaneGABARITO
Explicação
Dexrazoxane can reduce anthracycline induced cardiotoxicity, which is mediated in part by free radical formation and iron dependent oxidative injury. Doxorubicin is the classic association. Ver explicação completa e trilha adaptativa →